Laetiporus sulphureus polysaccharides mitigate colitis by reshaping the gut microbiota and regulating immune responses

硫磺菌多糖通过重塑肠道菌群和调节免疫反应来缓解结肠炎

阅读:1

Abstract

BACKGROUND: Inflammatory bowel disease (IBD) involves epithelial barrier disruption, immune dysregulation, and microbial imbalance. The present study investigated the protective mechanisms of Laetiporus sulphureus polysaccharides (LSP) in dextran sulfate sodium (DSS)-induced colitis, focusing on intestinal barrier restoration, immunomodulation, and gut microbiota remodeling. METHODS: LSP was structurally characterized using HPLC, FTIR, and SEM analyses, revealing a heteropolysaccharide primarily composed of glucose (55.16%), galactose (16.55%), and mannose (13.52%). Experimental colitis was induced in BALB/c mice with 3% DSS, followed by oral LSP administration (200 or 400 mg/kg). Disease severity, histopathology, barrier markers, cytokine profiles, macrophage polarization, and gut microbiota composition were evaluated using biochemical assays, immunofluorescence, IHC, and 16S rRNA sequencing. RESULTS: LSP significantly mitigated DSS-induced colitis by reducing the disease activity index by approximately 60% (∼2.5-fold, p < 0.001) and restoring colon length (∼1.5-fold, p < 0.01). Barrier integrity improved via enhanced mucin-2 expression (∼3.5-fold) and tight junction proteins Occludin, Claudin-1, and ZO-1 (∼5-9-fold). LSP suppressed pro-inflammatory cytokines TNF-α, IL-6, and IL-1β (∼2-3-fold) while upregulating anti-inflammatory mediators IL-10 and TGF-β (∼2.5-3-fold), reflecting a rebalanced mucosal immune milieu. 16S rRNA sequencing demonstrated reversal of DSS-induced dysbiosis, characterized by a reduction in pathogenic Escherichia-Shigella (∼3.8-fold) and Enterobacteriaceae (∼3.5-fold), and enrichment of beneficial taxa including Lactobacillus, Bifidobacterium, and Ruminococcus (∼2-4-fold). CONCLUSION: LSP exerts multi-targeted protection against colitis by reinforcing epithelial barrier function, attenuating inflammation, and reshaping gut microbial ecology. These findings highlight LSP as a promising natural therapeutic candidate for IBD. Further metabolomic and meta transcriptomic analyses are warranted to elucidate the microbial metabolites and molecular pathways mediating these protective effects.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。